Lumos Pharma, Inc. LUMO
Institutional shares held
2.2 Million
0
calls
0
puts
Total value of holdings
$9.54M
$0
calls
$0
puts
Market Cap
$36.4M
8,396,070
Shares Out.
Institutional ownership
26.25%
# of Institutions
33
We take great care to ensure that the data presented and summarized in this overview for LUMOS PHARMA, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LUMO
View all-
Private Advisor Group, LLC745KShares$3.22 Million0.02% of portfolio
-
Goldman Sachs Group Inc New York, NY362KShares$1.57 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA244KShares$1.06 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny214KShares$925,8140.0% of portfolio
-
Jefferies Financial Group Inc. New York, NY121KShares$522,4180.0% of portfolio
-
Jefferies Group LLC New York, NY121KShares$522,4180.01% of portfolio
-
Greenwich Wealth Management LLC Greenwich, CT76.3KShares$330,5560.02% of portfolio
-
Wells Fargo & Company San Francisco, CA65KShares$281,3670.0% of portfolio
-
Geode Capital Management, LLC Boston, MA55.1KShares$238,7900.0% of portfolio
-
Black Rock Inc. New York, NY41.1KShares$177,9800.0% of portfolio
Latest Institutional Activity in LUMO
Top Purchases
Top Sells
About LUMO
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Insider Transactions at LUMO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 06
2024
|
John C. Mc Kew Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,407
-21.21%
|
$3,407
$1.89 P/Share
|
|
Aug 01
2024
|
John C. Mc Kew Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,593
-9.02%
|
$1,593
$1.79 P/Share
|
|
Aug 01
2024
|
Lori D Lawley Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
229
-1.83%
|
$229
$1.79 P/Share
|
|
Jul 01
2024
|
Pisit Duke Pitukcheewanont Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
274
-1.6%
|
$548
$2.26 P/Share
|
|
Jun 01
2024
|
Pisit Duke Pitukcheewanont Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
320
-1.89%
|
$640
$2.25 P/Share
|
|
Apr 03
2024
|
John C. Mc Kew Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,214
-11.43%
|
$4,428
$2.77 P/Share
|
|
Apr 01
2024
|
Aaron Schuchart Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+13.02%
|
$2,000
$2.84 P/Share
|
|
Apr 01
2024
|
Richard J Hawkins Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,522
-0.2%
|
$3,044
$2.84 P/Share
|
|
Apr 01
2024
|
Richard J Hawkins Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+0.59%
|
$9,000
$2.84 P/Share
|
|
Apr 01
2024
|
John C. Mc Kew Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,036
-5.08%
|
$2,072
$2.84 P/Share
|
|
Apr 01
2024
|
John C. Mc Kew Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+8.93%
|
$4,000
$2.84 P/Share
|
|
Apr 01
2024
|
Pisit Duke Pitukcheewanont Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+26.17%
|
$12,000
$2.84 P/Share
|
|
Apr 01
2024
|
Lori D Lawley Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
274
-2.14%
|
$548
$2.84 P/Share
|
|
Apr 01
2024
|
Lori D Lawley Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+7.25%
|
$2,000
$2.84 P/Share
|
|
Apr 01
2024
|
Bradley J Powers General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
342
-5.14%
|
$684
$2.84 P/Share
|
|
Apr 01
2024
|
Bradley J Powers General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
900
+11.92%
|
$1,800
$2.84 P/Share
|
|
Feb 06
2024
|
John C. Mc Kew Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
438
-2.32%
|
$1,314
$3.03 P/Share
|
|
Feb 01
2024
|
John C. Mc Kew Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
366
-1.91%
|
$1,098
$3.01 P/Share
|
|
Feb 01
2024
|
Bradley J Powers General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
240
-4.01%
|
$720
$3.01 P/Share
|
|
Feb 01
2024
|
Aaron Schuchart Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
202
-3.43%
|
$606
$3.01 P/Share
|
Last 12 Months Summary
Buy / Acquisition
15.4K
Shares
From
6
Insiders
| Grant, award, or other acquisition | 15.4K shares |
|---|
Sell / Disposition
13.4K
Shares
From
7
Insiders
| Payment of exercise price or tax liability | 7.3K shares |
|---|---|
| Open market or private sale | 6.06K shares |